Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway
Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germinal center (GC) dependent process. However, clinic...
Main Authors: | Seema R. Patel, Taran S. Lundgren, Wallace Hunter Baldwin, Courtney Cox, Ernest T. Parker, John F. Healey, Ryan P. Jajosky, Patricia E. Zerra, Cassandra D. Josephson, Christopher B. Doering, Sean R. Stowell, Shannon L. Meeks |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.880829/full |
Similar Items
-
The Immune Response to the fVIII Gene Therapy in Preclinical Models
by: Seema R. Patel, et al.
Published: (2020-04-01) -
Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity
by: Patricia E. Zerra, et al.
Published: (2022-07-01) -
Early IgE Production Is Linked with Extrafollicular B- and T-Cell Activation in Low-Dose Allergy Model
by: Dmitrii Borisovich Chudakov, et al.
Published: (2022-06-01) -
Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
by: Glaivy Batsuli, et al.
Published: (2023-08-01) -
Extrafollicular Adenomatoid Odontogenic Tumors: A Series of Five Rare Cases with an Insight into Its Clinicopathological Aspects
by: Debarati Ray, et al.
Published: (2024-12-01)